Kraematon Investment Advisors’s GSK GSK Stock Holding History

Kraematon Investment Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-377	Closed	-$13.3K	–	146
2022 Q4	$13.3K	Buy	+377	New	+$12.6K	0.01%	189

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kraematon Investment Advisors's GSK Position: Q1 2023 in Review

Kraematon Investment Advisors sold out of GSK (GSK) in Q1 2023, closing a stake of 377 shares — an estimated $13.3K sold.

Kraematon Investment Advisors first reported a position in GSK in Q4 2022 and held it in 1 quarter. The position peaked at $13.3K in Q4 2022. 809 funds tracked by Wall St. Rank hold GSK as of Q1 2023.

Kraematon Investment Advisors reported no remaining GSK position as of Q1 2023 after selling out during the quarter.
Kraematon Investment Advisors sold 377 GSK shares in Q1 2023, an estimated $13.3K.
Kraematon Investment Advisors first reported a position in GSK in Q4 2022 and held it in 1 quarter.
Kraematon Investment Advisors's GSK position peaked at $13.3K in Q4 2022.
809 funds tracked by Wall St. Rank held GSK as of Q1 2023.

Based on Kraematon Investment Advisors's 13F filing for Q1 2023, filed 13 Apr 2023.